Genomtec S.A. (WSE:GMT)

Market Cap	77.28M -20.5%
Revenue (ttm)	15.00K +1,400.0%
Net Income	-11.01M
EPS	-0.73
Shares Out	15.06M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	79,637
Average Volume	48,799
Open	5.14
Previous Close	4.83
Day's Range	5.00 - 5.44
52-Week Range	3.25 - 8.59
Beta	0.42
RSI	58.25
Earnings Date	Apr 29, 2026

About Genomtec

Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company’s flagship project is the Genomtec ID, a diagnostic platform that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analysis of biological material of patients using swabs, urine, and saliva. It also develops SNAAT chemistry for mutation detection in oncology. In addition, ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2008
• Employees: 26
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: GMT

Financial Performance

In 2024, Genomtec's revenue was 1,000, a change of 0.00% compared to the previous year's 1,000. Losses were -11.21 million, 24.4% more than in 2023.